Login to Your Account

Out of the fast lane

A potential 2018 launch for DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine (Rova-T) is off the table, as Abbvie Inc. said it will not seek accelerated approval in third-line small-cell lung cancer (SCLC), based on the "magnitude of effect across multiple parameters" in the phase II TRINITY study, news that sent shares of the large-cap stock (NASDAQ:ABBV) sinking 12.8 percent Thursday, losing $14.35 to close at $98.10.

more »

Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.



Partners in Focus